PAD Profile : Dexamethasone - Retinal Vein Occlusion

PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Dexamethasone - Retinal Vein Occlusion

PAD Profile : Dexamethasone - Retinal Vein Occlusion Important

Keywords :

RVO, CRVO, BRVO, macular oedema, branch retinal vein occlusion

Brand Names Include :

Ozurdex

Important Information :

Ophthalmology specialists only

Traffic Light Status

Status 1 of 1.

Status :

Red

Formulations :

Intravitreal implant

Trust Alignment :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

BNF NICE SPC

NFD1

ICB

BlueTeq

NICE

Comments :

No comments returned.

Documents :

Guidelines

No guidelines returned.

Other Drugs

Ranibizumab

Other Indications

Additional Documents

Type

Document

Review Date

Evidence Review

Achieving and demonstrating compliance with NICE TA and HST guidance - NICE January 2016

Webpage

NICE TA229 - Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion - July 2011

Committee Recommendations

Date

Committee Name

Narrative

05 October 2016

Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The PCN recommends intravitreal dexamethasone (Ozurdex) as a treatment option for the first line treatment of visual impairment caused by macular oedema secondary to branch or central retinal vein occlusion in line with NICE TA 229 (July 2011) and the NICE FAQ document relating to local formularies (link to document below). Intravitreal dexamethasone will be considered RED on the traffic light system

Associated BNF Codes

11. Eye

11.04.01. Corticosteroids